Application of AF9 in the diagnosis and treatment of AML
By preventing AF9 from binding to the TRiC complex, the AF9(59-78) peptide reverses the liquid-gel phase transition to a liquid-liquid phase transition, solving the problem of poor efficacy in AML treatment and providing a new AML treatment method that inhibits AML cell proliferation and drug resistance.
Patent Information
- Application Number
- CN202310386598.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-04
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-04-04
AI Technical Summary
In the current technology, the treatment effect of acute myeloid leukemia (AML) is limited, especially the survival rate of elderly patients is low, and the regulatory mechanism of AF9 in AML is not clear, resulting in a lack of effective therapeutic targets.
Research has shown that AF9 promotes liquid-gel phase transition in AML. AF9(59-78) peptides were prepared to prevent AF9 from binding to the TRiC complex and interfering with its folding, thereby reversing the liquid-gel phase transition to a liquid-liquid phase transition and inhibiting AML cell proliferation and drug resistance.
AF9(59-78) peptide effectively inhibits AML cell proliferation and drug resistance, providing a new AML treatment tool and improving treatment efficacy.
Smart Images

Figure CN116769907B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the fields of biomedicine and molecular biology, specifically relating to the application of AF9 in the diagnosis and treatment of AML. Background Technology
[0002] The information disclosed in the background section of this invention is intended only to enhance the understanding of the overall background of the invention and is not necessarily to be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.
[0003] Acute myeloid leukemia (AML) is a rapidly progressing malignant hematopoietic stem cell disease characterized by progenitor cell differentiation arrest and is most common in adults. Despite classic treatments over the past few decades, AML, as a catastrophic diagnosis, has seen little improvement in survival rates and remains historically deadly. With conventional chemotherapy regimens, the 5-year overall survival rate is 40% for patients under 60 years of age, and less than 15% for those over 60. While treatments targeting apoptosis, DNA repair, mitochondrial function, FLT3 inhibitors, and IDH inhibitors are under clinical trials, their efficacy remains unknown. Therefore, it is imperative to explore the underlying mechanisms of AML progression to investigate new therapeutic targets.
[0004] It is well known that AF9, as an MLL-AF9 fusion gene, can induce myeloid leukemia in mice and humans. However, researchers have only found that the C-terminal AHD domain plays an important role in MLL-AF9 leukemia, positively regulating transcriptional elongation which ceases after gene fusion, but the YEATS domain has received little attention. The inventors have discovered that the pathophysiological and fundamental molecular role of AF9 in regulating gene expression in AML remains poorly understood. Summary of the Invention
[0005] To address the shortcomings of existing technologies, the present invention aims to provide the application of AF9 in the diagnosis and treatment of AML. This invention, through research, discovered that AF9 promotes AML proliferation and drug resistance through a liquid-gel phase transition. The acetylation-deficient mutant AF9(3A) can only undergo a liquid-liquid phase transition and has lost its ability to promote AML. Proper folding by the TCP-1 cyclic complex (TRiC complex) is crucial for AF9 to form gelatinous aggregates, but misfolded AF9(3A) can only undergo a liquid-liquid phase transition. Finally, an AF9(59-78) peptide was created to interfere with AF9's folding by preventing its binding to TRiC, thereby reversing the liquid-gel phase transition to a liquid-liquid phase transition and inhibiting AML. Based on the above research results, this invention is thus completed.
[0006] Specifically, the technical solution of the present invention is as follows:
[0007] In a first aspect, the invention provides the use of substances for detecting the AF9 encoding gene and its expression products in the preparation of products for the diagnosis, detection, monitoring, or prognostic assessment of acute myeloid leukemia.
[0008] This invention has found that AF9 is associated with the onset and poor prognosis of AML. Specifically, AML patients express higher levels of AF9 than healthy controls, indicating a link between AF9 and leukemia development. Furthermore, AML patients with high AF9 expression have significantly shorter overall survival, more severe disease, and greater drug resistance. Therefore, the prognostic assessment should at least include an evaluation of overall survival, drug resistance, and disease severity in AML patients.
[0009] A second aspect of the invention provides the use of any one or more of the following: (1) Inhibiting the AF9 coding gene and its expression product and / or substances that reduce its activity.
[0010] a) Inhibit AF9 from undergoing a liquid-gel phase transition or prepare products that inhibit AF9 from undergoing a liquid-gel phase transition;
[0011] b) Promote the liquid-liquid phase transition of AF9 or prepare products that promote the liquid-liquid phase transition of AF9;
[0012] c) Inhibit AML cell proliferation or prepare products that inhibit AML cell proliferation;
[0013] d) Inhibit AML resistance or prepare products that inhibit AML resistance;
[0014] e) Prepare products for the treatment of AML.
[0015] A third aspect of the present invention provides a method for treating acute myeloid leukemia, the method comprising administering the above-mentioned AF9(59-78) peptide or a corresponding drug to a subject.
[0016] The beneficial technical effects of one or more of the above technical solutions are as follows:
[0017] The above-mentioned technical approach revealed that AF9 is associated with leukemia occurrence and poor prognosis in AML patients, and that AF9 undergoes a liquid-gel phase transition both in vivo and in vitro. Furthermore, this approach demonstrated that the AF9(3A) mutant loses its ability to recognize acetylated proteins and cannot form gel-like particles, thus failing to promote AML cell proliferation and drug resistance. Finally, this approach demonstrated that the AF9 and TRiC complex is essential for proper folding and plays a crucial role in the AF9 liquid-gel phase transition and the promotion of AML. The AF9(59-78) peptide inhibits AML by interfering with AF9 folding through its binding to TRiC, reversing the AF9 liquid-gel phase transition into a liquid-liquid phase transition.
[0018] In summary, the above results demonstrate that AF9 promotes AML proliferation and drug resistance through colloidal phase transition, and that the AF9(59-78) peptide is a promising therapeutic tool for AML, thus possessing significant practical application value. Attached Figure Description
[0019] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an improper limitation of the invention.
[0020] Figure 1 In this embodiment of the invention, AF9 expression is associated with AML progression and prognosis; wherein, (A) single-cell sequencing of CD34+ cells from bone marrow samples of healthy controls obtained from PanglaoDB was used to analyze AF9 expression; (B) AF9 expression was obtained from 173 AML patients and 70 healthy controls obtained from the TCGA database; (C) overall survival analysis based on AF9 expression in 106 AML patients obtained from the TCGA database; (D) remission and refractory / relapse rates in 20 AML patients with high AF9 expression and 20 with low AF9 expression; (E) the proportion of bone marrow CD45+ cells in tumor-transplanted mice derived from patients with high and low AF9 expression before and after treatment with doxorubicin and cytarabine, n=4; (F) the proportion of spleen CD45+ cells after treatment with doxorubicin and cytarabine. n=4, *P<0.05, **P<0.01; ##P<0.01, ###P<0.001.
[0021] Figure 2 In this embodiment of the invention, AF9 promotes the proliferation and drug resistance of AML cells in vitro and in vivo; wherein, (A) EdU experiment shows the proportion of positive cells in OCI-AML3 and Kasumi-1 in NC, shAF9-1 and shAF9-2 groups; (B) In CCK8 experiment, OD values were recorded at 0, 12, 24, 48 and 72 hours and the data were used to calculate proliferation based on the 0 hour result; (C) Colony formation experiment shows long-term proliferation of OCI-AML3 and Kasumi-1, and the statistical results are shown in (D); (E) Flow cytometry was used to analyze the proliferation and drug resistance of AML cells in NC, shAF9-1 and shAF9-2 groups. Apoptosis of OCI-AML3 and Kasumi-1 cells in the shAF9-2 group after IDA treatment was analyzed, and the statistical results are shown in (F); (G) Spleen weight of mice with OCI-AML3 transplantation in the NC, shAF9-1 and shAF9-2 groups before and after treatment with doxorubicin and cytarabine, n=5 (H) The proportion of OCI-AML3 cells in the bone marrow and spleen of NSG mice was analyzed by flow cytometry, n=5, *P<0.05; **P<0.01; ***P<0.001.##P<0.01,####P<0.0001.
[0022] Figure 3This invention illustrates the liquid-gel phase transition of AF9 in this embodiment; wherein, (AB) immunofluorescence images and particle counts of CD34-, CD34+, and AML cells (controls), scale bar, 5 μm; (C) analysis of the disordered region of AF9 using IUPred2A; (D) AF9 purified with different concentrations of polymerizing agent showed a concentration-dependent increase in turbidity; (E) AF9 droplets formed in 20% PEG 1000 disappeared after treatment with 1,6-hexanediol, while AF9 droplets formed in 40% PEG 8000 did not disappear after treatment with 1,6-hexanediol, scale bars up, 5 μm; scale bars down, 10 μm; (F) two-point fusion under treatment with 40 mM NaCl and 20% PEG 1000, scale bars, 2 μm; (G) confocal microscopy image of HeLa cells transfected with AF9 and treated with 1,6-hexanediol for 15 minutes, scale bar. bars, 5μm; (HI) Fluorescence bleaching recovery assay of HeLa cells after AF9 transfection, images shown in (H), zoom in using the selection box, scale bars left, 2μm. Scale bars right, 1μm; curves shown in (I), n=3; (J) Confocal microscopy images of OCI-AML3 cells and cells treated with TSA and NAM for 3 hours or not, scale bars, 5μm; (K) Quantitative analysis of the number of particles in each cell, ****P<0.0001.
[0023] Figure 4 This invention illustrates the liquid-liquid phase transition of the AF9(3A) mutant in an embodiment of the present invention. (A) An illustration of the structures of AF9 and AF9(3A), with the three mutated amino acids, F59A, G77A, and Y78A, magnified. (B) A confocal microscopy image of HeLa cells expressing the AF9 mutant, scale bars, 10 μm. (C) Cell particle number, average area, and fluorescence ratio. (D) Fluorescence bleaching recovery experiment of HeLa cells expressing the AF9 mutant. ***P<0.001,****P<0.0001.
[0024] Figure 5In this embodiment of the invention, the AF9(3A) mutant cannot promote AML in vitro and in vivo; wherein, (A) the proportion of EdU positive cells in OCI-AML3 and Kasumi-1 cells in the NC, AF9, and AF9(3A) groups; (B) the proliferation of OCI-AML3 and Kasumi-1 cells in the NC, AF9, and AF9(3A) groups analyzed by CCK-8; (C) the colony formation experiment of OCI-AML3 and Kasumi-1 cells in the NC, AF9, and AF9(3A) groups; (DE) the apoptosis of OCI-AML3 and Kasumi-1 cells after IDA treatment, and the statistical results are shown in (E); (F) confocal microscopy images and particle counts for each cell, scaled. Bars, 5 μm; (G) In vivo imaging of OCI-AML3 transplanted mice in the NC, AF9 and AF9(3A) groups showing disease burden; (H) Flow cytometry analysis of the proportion of OCI-AML3 in bone marrow and spleen of NSG mice before and after treatment with doxorubicin and cytarabine; (I) GO analysis of RNA sequencing of the top ten altered biological processes of OCI-AML3 overexpression in AF9 and AF9(3A), *P<0.05,**P<0.01,***P<0.001,****P<0.0001.###P<0.001,####P<0.0001.
[0025] Figure 6In this embodiment of the invention, the AF9 (59-78) peptide reverses the liquid-gel phase transition of AF9 and thus affects the progression of AML by interfering with the binding of AF9 to TRiC; wherein, (A) mass spectrometry analysis of IP results showed 50 proteins that interact with AF9 but not with AF9 (3A); (B) protein-protein interactions between AF9 and CCT1, CCT3, CCT6A and CCT7A were verified by immunoprecipitation experiments; (C) protein-protein interactions between AF9 and AF9 (3A) and CCT6A were verified by immunoprecipitation experiments; (D) protein-protein interactions between AF9 and AF9 (3A) and c-Myc were verified by immunoprecipitation experiments; (E) immunofluorescence images of AF9 and AF9 (3A) in HeLa cells using c-Myc antibody, scaled. Scale bars, 5 μm. Statistical results are shown in (F); (G) Structure of AF9(59-78) peptide; (H) Verification of protein-protein interactions between AF9 and CCT6A with and without AF9(59-78) treatment by immunoprecipitation assay; (I) Confocal microscopy images of HeLa cells overexpressing AF9 and AF9(59-78)-EGFP, scale bars, 10 μm. Statistical results are shown in (J). (K) Fluorescence bleaching recovery assay of HeLa cells overexpressing AF9 and EGFP-N1 or AF9(59-78)-EGFP; (L) Short-term proliferation analysis of OCI-AML3 cells expressing EGFP-N1 or AF9(59-78)-EGFP using EdU assay; (M) Long-term proliferation analysis of OCI-AML3 cells expressing EGFP-N1 or AF9(59-78)-EGFP using CCK-8 assay; (N) Quantitative analysis of apoptosis in OCI-AML3 cells expressing EGFP-N1 or AF9(59-78)-EGFP, ***P<0.001, ****P<0.0001.
[0026] Figure 7 In this embodiment of the invention, (A) the immunoprecipitation experiment was used to verify the successful transfection of OCI-AML3 and Kasumi-1 cells with control and two viruses that downregulated AF9, and the statistical results are shown in (B); (C) spleen photographs of mice with OCI-AML3 transplantation in the NC, shAF9-1 and shAF9-2 groups before and after treatment with doxorubicin and cytarabine, n=5; (D) the immunoprecipitation experiment was used to verify the successful transfection of OCI-AML3 and Kasumi-1 cells with overexpression of control, AF9 and AF9(3A) viruses; (E) spleen photographs and weight statistics of mice with OCI-AML3 transplantation in the NC, AF9 and AF9(3A) groups before and after treatment with doxorubicin and cytarabine, n=5. Detailed Implementation
[0027] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of this application. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application pertains.
[0028] It should be noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the exemplary embodiments according to this application. As used herein, the singular form is intended to include the plural form as well, unless the context clearly indicates otherwise. Furthermore, it should be understood that when the terms "comprising" and / or "including" are used in this specification, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.
[0029] The present invention will now be further illustrated with specific examples. These examples are for illustrative purposes only and do not limit the scope of the invention. Unless otherwise specified, experimental conditions not explicitly stated in the examples are generally performed under conventional conditions or as recommended by the reagent company. Unless otherwise specified, all reagents and consumables used in the following examples are commercially available.
[0030] Terminology Explanation:
[0031] Liquid-liquid phase separation: When protein molecules reach a certain concentration, they precipitate small droplets in the solution, which can be recovered after fluorescent bleaching.
[0032] Liquid-gel phase separation: When protein molecules reach a certain concentration, they precipitate into gel-like droplets in the solution, which cannot be recovered after fluorescent bleaching.
[0033] As previously mentioned, AF9, as an MLL-AF9 fusion gene, can induce myeloid leukemia in mice and humans. However, researchers have only found that the C-terminal AHD domain plays an important role in MLL-AF9 leukemia, positively regulating transcriptional elongation which ceases after gene fusion, but the YEATS domain has received little attention. The pathophysiology and underlying molecular role of AF9 in regulating gene expression in AML remain poorly understood.
[0034] In view of this, in a typical embodiment of the present invention, the use of a substance for detecting the AF9 encoding gene and its expression product in the preparation of a product for the diagnosis, detection, monitoring or prognostic assessment of acute myeloid leukemia is provided.
[0035] This invention has found that AF9 is associated with the onset and poor prognosis of AML. Specifically, AML patients express higher levels of AF9 than healthy controls, indicating a link between AF9 and leukemia development. Furthermore, AML patients with high AF9 expression have significantly shorter overall survival, more severe disease, and greater drug resistance. Therefore, the prognostic assessment should at least include an evaluation of overall survival, drug resistance, and disease severity in AML patients.
[0036] The AF9 encoding gene and its expression product can both be of human origin, and the expression product of the AF9 encoding gene can obviously be the AF9 protein.
[0037] The substance for detecting the AF9 encoding gene and its expression product includes substances that detect AF9 transcription in the sample based on high-throughput sequencing and / or quantitative PCR and / or probe hybridization; or substances that detect AF9 protein expression in the sample based on immunoassay.
[0038] In another specific embodiment of the present invention, methods including but not limited to liquid phase hybridization, Northern hybridization, nucleic acid chips, RAKE method, and in situ hybridization can be used to detect the transcription of AF9 in the sample; methods including but not limited to Western blotting, ELISA, colloidal gold test strips, and protein chips can be used to detect the expression of AF9 protein in the sample.
[0039] The sample can be a bone marrow sample from the subject.
[0040] In another specific embodiment of the present invention, the use of substances that inhibit the AF9 coding gene and its expression product and / or reduce its activity is provided in any one or more of the following:
[0041] a) Inhibit AF9 from undergoing a liquid-gel phase transition or prepare products that inhibit AF9 from undergoing a liquid-gel phase transition;
[0042] b) Promote the liquid-liquid phase transition of AF9 or prepare products that promote the liquid-liquid phase transition of AF9;
[0043] c) Inhibit AML cell proliferation or prepare products that inhibit AML cell proliferation;
[0044] d) Inhibit AML resistance or prepare products that inhibit AML resistance;
[0045] e) Prepare products for the treatment of AML.
[0046] The substances that inhibit the AF9 encoding gene and its expression products and / or reduce its activity include, but are not limited to, RNA interference molecules or antisense oligonucleotides targeting AF9, small molecule inhibitors, shRNA (small hairpin RNA), siRNA (small interfering RNA), substances that implement lentiviral infection or gene knockout, and specific antibodies against the AF9 protein itself or its upstream and downstream molecules, such as anti-AF9 antibodies.
[0047] Specifically, this invention discovered through research that the occurrence of the liquid-gel phase transition of AF9, i.e. particle formation, depends on the disordered region of AF9, and the three amino acid sites F59, G77, and Y78 are important for the liquid-gel phase transition of AF9 (i.e., the formation of gel-like particles). Therefore, an AF9(3A) mutant was constructed. The AF9(3A) mutant is based on the AF protein and the mutated amino acids of the AF9(3A) mutant are specifically F59A, G77A, and Y78A. The NCBI accession number of the AF9 protein is NP_004520.2.
[0048] Furthermore, this invention has found that a properly folded AF9 liquid-gel phase transition can promote AML. Specifically, three amino acid sites of AF9 (F59, G77, and Y78) crucial for its acetylation reading are essential for binding to TRiC and proper folding. Properly folded AF9 undergoes a liquid-gel phase transition, promoting the formation of an effective functional complex, thereby influencing AML cell proliferation and drug resistance. Therefore, this invention further designs an AF9 (59-78) peptide covering the aforementioned three important amino acid sites, which inhibits AML cell proliferation and drug resistance by suppressing the binding of AF9 protein to TRiC and the formation of the liquid-gel phase transition.
[0049] The nucleotide sequence of the AF9(59-78) peptide is shown below:
[0050] GCCACCATGGAGCAGAAGCTGATCTCAGAGGAGGACCTGAGCTTTCCTAGGCCAAA AAGAGTGTGCAAAGATCCACCTTACAAAGTAGAAGAATCTGGGTATGCT (SEQ ID NO. 1).
[0051] The product can be a drug or an experimental reagent, with the experimental reagent intended for basic research. For example, this product can be used to regulate the proliferation and drug resistance models of AML cells in vitro, thereby establishing an efficient and economical AML cell model, which can then be used to study the related mechanisms of AML development (such as liquid-colloid phase transition and liquid-liquid phase transition).
[0052] According to the present invention, when the product is a drug, the drug further includes at least one inactive pharmaceutical ingredient.
[0053] The inactive components of the drug can be pharmaceutically commonly used carriers, excipients, and diluents. Furthermore, according to conventional methods, it can be formulated into oral, topical, suppository, and sterile injectable solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and sprays.
[0054] The non-pharmaceutical active ingredients that may be included, such as carriers, excipients, and diluents, are well known in the art, and those skilled in the art can determine that they meet clinical standards.
[0055] Preferably, the carrier, excipients, and diluents include, but are not limited to, lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylparaben, propylparaben, talc, magnesium stearate, and mineral oil.
[0056] In another specific embodiment of the present invention, the drug can be administered to humans and non-human mammals, such as mice, rats, guinea pigs, rabbits, dogs, monkeys, orangutans, etc.
[0057] In another specific embodiment of the present invention, a method for treating acute myeloid leukemia is provided, the method comprising administering the above-mentioned AF9(59-78) peptide or corresponding drug to a subject.
[0058] It should be noted that, according to the present invention, the concept of "treatment" means any measure applicable to the treatment of acute myeloid leukemia, or preventive treatment of the disease or its symptoms, or prevention of recurrence of the disease, such as recurrence after the end of a treatment period or treatment of symptoms of an already occurring disease, or preemptive prevention, suppression or reduction of the occurrence of such disease or symptoms.
[0059] In another specific embodiment of the invention, the therapeutic agent of the invention can be administered into the body by known means. For example, it can be delivered to the tissue of interest via intravenous systemic delivery or local injection. Alternatively, it can be administered via intravenous, percutaneous, intranasal, mucosal, or other delivery methods. Such administration can be performed via a single dose or multiple doses. Those skilled in the art will understand that the actual dose to be administered in the invention can vary considerably depending on a variety of factors, such as the target cells, biological type or tissue thereof, the general condition of the subject to be treated, the route of administration, the manner of administration, etc.
[0060] The following examples further illustrate the present invention, but do not constitute a limitation thereof. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the invention. The following examples illustrate test methods with specific conditions, which are generally performed under conventional conditions.
[0061] Example
[0062] method
[0063] Clinical samples
[0064] All AML patients were diagnosed according to NCCN guidelines. Bone marrow samples from all newly diagnosed and relapsed patients were obtained from Qilu Hospital of Shandong University in Jinan, Shandong, China. Control samples were obtained from healthy donors without malignant bone marrow disease. Informed consent was obtained from the Medical Ethics Committee of Qilu Hospital. The experimental procedures for all clinical samples were in accordance with the Declaration of Helsinki of the World Medical Association.
[0065] Cell culture, transfection and infection
[0066] Kasumi-1 and OCI-AML3 cells were cultured in serum-free modified Iskov medium with 20% fetal bovine serum and 1% penicillin / streptomycin. HeLa cells were cultured in modified Duchenne Eagle medium with 10% fetal bovine serum and 1% penicillin / streptomycin. Cells were cultured at 37°C and 5% CO2. Transfection was performed using Lipofectamine 2000 according to the manufacturer's instructions. Viral infection was performed by adding up- and down-regulating virus to the inoculated cells and centrifuging at 1000g for 1 hour. After 24 hours of culture, the medium was changed and the cells were cultured for another 48 hours in preparation for subsequent experiments.
[0067] Cell proliferation and apoptosis
[0068] Cells were seeded in 96-well plates, and 10 μL of CCK-8 was added to 100 μL of culture medium. After incubation at 37°C for 4 hours, cell readings were taken at 450 / 630 nm using a microplate reader. Cell viability was the percentage of surviving cells relative to the control. Colony formation was performed by seeding cells in methylcellulose medium and counting colonies 14 days later, according to the manufacturer's instructions. The EdU assay was performed using iClick according to the manufacturer's instructions. TM EdU Andy Fluor TM 647 Flow Cytometry Assay Kit. Apoptosis assays involved washing cells with PBS, followed by staining with APC-Annexin-V and 7-AAD at room temperature for 15 minutes. EdU and apoptosis assays were performed using flow cytometry.
[0069] Real-time quantitative PCR
[0070] RNA was extracted using Trizol according to the instructions and then reverse transcribed into cDNA using reverse transcriptase. Real-time quantitative PCR involves mixing cDNA, primers, and TB Green Premix Ex Taq. TM The mixture was then amplified using a Light Cycler 480 II PCR instrument according to the instructions. All data were normalized to GAPDH expression. High and low AF9 expression were distinguished based on the median AF9 expression in AML patients.
[0071] Immunoblotting
[0072] Cells were washed with PBS and then lysed on ice for 30 minutes with lysis buffer containing protease and phosphatase inhibitors. Proteins in the cell lysate were then separated by SDS gel electrophoresis and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk at room temperature and incubated overnight with primary antibodies, using GAPDH as a control. Primary antibodies included anti-AF9 and anti-GAPDH. Secondary antibodies included HRP-bound goat anti-rabbit IgG (H+L) and HRP-bound goat anti-mouse IgG (H+L). Finally, protein bands were exposed using a ChampChemi gel imaging system.
[0073] Purification of recombinant proteins
[0074] AF9 was expressed and purified in BL21-competitive *E. coli*. Cells were first cultured at 37°C in LB medium containing 50 μg / mL kanamycin until an OD value of 0.6 was achieved, followed by induction with 500 μM IPTG at 19°C. The cells were then sonicated in a buffer containing 300 mM NaCl, 10 mM Tris8, 0.2 mM imidazole, and 0.5 mM PMSF, followed by two centrifugations at 15,000 rpm for 30 minutes at 4°C. The supernatant was incubated with Ni-NTA and washed with a wash buffer containing 300 mM NaCl, 10 mM Tris8, and 20 mM imidazole. Elution was then performed with an elution buffer containing 300 mM NaCl, 10 mM Tris8, and 100 mM imidazole to obtain the protein. Finally, the protein was purified by ultrafiltration and centrifugation.
[0075] Image analysis of AF9 and its mutants
[0076] Particle analysis was performed using ImageJ software. The results included particle number, average particle area per cell, and average fluorescence intensity. The fluorescence ratio was the proportion of the average fluorescence intensity of particles per cell to the total average fluorescence intensity of the entire cell. Immunoprecipitation, mass spectrometry, and co-immunoprecipitation experiments were also performed.
[0077] Cells were lysed using NP-40 lysis buffer containing 50 mM Tris-HCl (pH 7.2), 250 mM NaCl, 0.1% NP-40, 2 mM EDTA, 10% glycerol, protease inhibitors, and phosphatase inhibitors. Total protein was incubated at 4°C with agarose-bound anti-GFP antibody for 16 hours, followed by washing five times with the antigen-antibody-agarose complex and detection using an SDS gel. Bands were stained with Coomassie Brilliant Blue, and lanes were cut and analyzed using Thermo's Q Exactive... TM Mass spectrometry analysis was performed using an LC / MS system. Proteins in the AF9 and AF9(3A) groups that achieved a Score Sequest HT ≥ 1.5 were those interacting with AF9 or AF9(3A). After washing with the antigen-antibody-agarose complex, Western blotting was performed using anti-GFP, anti-FLAG (CST), and anti-HA antibodies.
[0078] Droplet formation experiment
[0079] The purified protein was mixed with phase transition buffer and then photographed using a 63x lens on a Zeiss LSM 900 confocal microscope.
[0080] Immunofluorescence
[0081] OCI-AML3 and Kasumi-1 cells were fixed with 4% paraformaldehyde for 15 minutes, washed with PBS, and then blocked at room temperature with PBS containing 0.4% Triton X-100 and 10% fetal bovine serum for 20 minutes. Cells were then incubated overnight at 4°C with rabbit-derived anti-AF9 or anti-coilin antibody at a 1:200 dilution, followed by incubation with goat anti-rabbit Alexa Fluor 488 antibody. Finally, images were taken using a Zeiss LSM 900 confocal microscope. Primary bone marrow cells were incubated with APC-bound anti-CD34 antibody in the dark for 15 minutes before these steps, followed by washing with PBS.
[0082] Fluorescent bleaching recovery experiment
[0083] Fluorescence bleaching recovery experiments were performed on HeLa cells expressing AF9-EGFP and mutants using a Zeiss LSM 900 confocal microscope. Bleaching was performed on ZEN cells using a laser with a wavelength of 488 nm at 60% of the maximum laser intensity. Fluorescence recovery was observed and recorded at 2-second intervals using a 488 nm laser.
[0084] In vivo experiments
[0085] This study was conducted with the approval and guidance of the Animal Ethics Committee of Qilu Hospital. To establish a patient-derived tumor model, we administered 2 × 10⁻⁶ mg / L to NSG mice via tail vein injection. 6 Each mouse was injected with primary AML cells. The severity of leukemia was assessed using the proportion of CD45+ cells in the bone marrow and spleen. Figure 2 In this study, OCI-AML3 cells transfected with NC, shAF9-1, and shAF9-2 viruses were injected intravenously into the tail vein of 6-8 week old NSG mice. Figure 5 In this study, 6-8 week old NSG mice were intravenously injected with OCI-AML3 cells transfected with NC, AF9, and AF9(3A) viruses. EGFP fluorescence signal was detected using IVIS Spectrum to assess leukemia severity. EGFP-positive cells in the bone marrow and spleen were detected by flow cytometry. AML-treated mice were administered 1.2 mg / kg doxorubicin and 50 mg / kg cytarabine for three consecutive days four weeks after cell engraftment.
[0086] Data Analysis
[0087] An unpaired t-test was used to test for significant differences between the two groups. A p-value less than 0.05 was considered significant. The data were analyzed using GraphPadPrism 8.0.
[0088] result
[0089] AF9 expression is associated with AML progression and prognosis.
[0090] To investigate the function of AF9 in AML, we first analyzed single-cell RNA sequencing of PanglaoDB cells and found that AF9 was highly expressed in hematopoietic stem cells, and its expression decreased significantly with bone marrow differentiation, indicating that AF9 inhibits normal bone marrow cell production. Figure 1 A). Furthermore, according to the TCGA database, we found that AF9 expression was higher in AML patients than in healthy controls, suggesting that AF9 may be related to the pathogenesis of leukemia. Figure 1 B). Meanwhile, patients with high AF9 expression had significantly shorter overall survival, indicating that AF9 is also associated with poor prognosis in AML. Figure 1 C). Similarly, our analysis of clinical samples showed that AF9 expression levels were significantly higher in AML patients than in healthy controls. Figure 1 D). When AML patients were grouped according to their AF9 expression levels, we found that the high AF9 expression group had a higher proportion of relapsed / refractory patients compared to the low AF9 expression group. Figure 1(D) This further demonstrates that high AF9 expression is not only associated with the pathogenesis of leukemia but also with poor prognosis. We established a mouse model of leukemia tumor transplantation by intravenously transplanting patient bone marrow blast cells into NSG mice. By analyzing CD45+ cells in the bone marrow and spleen, we found that mice transplanted with high AF9 patient cells had more severe disease compared to mice transplanted with low AF9 expression cells. Figure 1 E and Figure 1 F). Mice that underwent chemotherapy and received transplants of patient cells expressing high levels of AF9 also showed greater drug resistance. Figure 1 E and Figure 1 In summary, our results demonstrate that AF9 is associated with the pathogenesis and poor prognosis of AML.
[0091] AF9 promotes the proliferation and drug resistance of AML cells in vitro and in vivo.
[0092] To further investigate the function of AF9 in AML, we performed loss-of-function experiments. First, we knocked down AF9 expression in OCI-AML3 and Kasumi-1 using short hairpin RNA and confirmed the knockdown effect using Western blotting. Figure 7 A and 7B). Then, we perform EdU ( Figure 2 A), CCK-8 Figure 2 B) and settlement formation experiments ( Figure 2 (C and 2D) It was found that downregulation of AF9 inhibited the short-term and long-term proliferation of OCI-AML3 and Kasumi-1, indicating that AF9 is required for the proliferation of AML cells in vitro. Furthermore, knockdown of AF9 led to a significant increase in apoptosis in AML cells treated with IDA, demonstrating the role of AF9 in mediating AML drug resistance in vitro. Figure 2 E and 2F). To demonstrate the effect of AF9 on AML in vivo, we transplanted AF9-knockdown OCI-AML3 cells into NSG mice. The results showed that, compared to control mice, AF9-downregulated mice had significantly lower body weight and bone marrow and spleen load, indicating that AF9 downregulation inhibits AML cell proliferation in vitro. Figure 2 H). Mice with downregulated AF9 treated with DOX and Ara-C experienced faster disease remission than control mice, indicating that AF9 is important for AML resistance. Figure 2 In summary, these data demonstrate that AF9 promotes the proliferation and drug resistance of AML cells both in vivo and in vitro.
[0093] AF9 undergoes liquid-gel phase transition
[0094] To detect AF9 expression in different cell types, we performed immunofluorescence and found that AF9 was expressed in healthy control CD34+ cells but not in CD34- cells. Furthermore, compared to healthy control CD34+ cells, AML patient CD34+ cells formed more granules (…). Figure 3 (A and 3B). Therefore, we hypothesize that AF9 possesses inherent biophysical properties that promote phase transitions to maintain AML. Next, we analyzed the amino acid sequence of AF9 using an algorithm to predict protein disorder regions and found that AF9 possesses a long disorder region and a tendency to undergo phase transitions (A and B). Figure 3 C). To assess whether AF9 could undergo a phase transition, we added PEG and NaCl to AF9 purified from E. coli. The results showed that AF9 formed liquid particles in low concentrations of low-polymer PEG and colloidal particles in high concentrations of high-polymer PEG. Figure 3 D). Furthermore, confocal imaging showed that AF9 could be dispersed in PEG 1000 by resuspending it in 1,6-hexanediol, but not in PEG 8000. Figure 3 E). Simultaneously, the formation of micron-sized spheres exhibits characteristics of a phase transition, namely, the polymerization of liquids (E). Figure 3 F). The results of AF9 purification demonstrated that AF9 undergoes a liquid-gel phase transition in high-polymerization buffer and a liquid-liquid phase transition in low-polymerization buffer. To further investigate whether AF9 forms particles in vivo, we ectopically expressed AF9-EGFP in HeLa cells and found that it can form particles in the cell nucleus, which do not disappear after treatment with 1,6-hexanediol. Figure 3 G). Then, we performed the fluorescence recovery after bleaching (FRAP) experiment. Similar to ENL in the same family, AF9's fluorescence could not be recovered (G). Figure 3 H and 3I). These results indicate that AF9 undergoes a liquid-gel phase transition in cells. Since the most reported function of AF9 is reading acetylation, we investigated whether this function is related to a phase transition in AML cells. OCI-AML3 and Kasumi-1 cells formed more particles after 3 hours of treatment with TSA and NAM, suggesting a potential link between AF9 phase transition and acetylation reading function. Figure 3 J and 3K). These results indicate that AF9 undergoes a liquid-colloid phase transition within cells.
[0095] The AF9(3A) mutant undergoes a liquid-liquid phase transition.
[0096] To further identify the domains required for the liquid-gel phase transition of AF9, we constructed three AF9 deletion mutants. AF9ΔC lacks the C-terminus, AF9(M) contains only the disorder region, and AF9(N) lacks both the disorder region and the C-terminus. We also constructed AF9(3A) mutants with three amino acid mutations crucial for acetylation reading: F59A, G77A, and Y78A. Figure 4 A). Then, we found that in HeLa cells, AF9, AF9ΔC, AF9(M), and AF9(3A) could all form particles, but AF9(N) could not, proving that the disordered region is indispensable for phase transitions. Figure 4B). Notably, AF9(M) forms fewer, larger, and more compact particles, indicating that it possesses the strongest ability to form particles, having only complete disordered regions. Compared to AF9, AF9(3A) exhibits a weaker phase transition ability, forming fewer particles. Figure 4 C). Meanwhile, similar to AF9, neither AF9ΔC nor AF9(M) could be recovered in the FRAP experiment, indicating that they had entered a stable gel-like state. Figure 4 D). In contrast, AF9(3A) showed rapid fluorescence recovery, indicating stronger fluidity and suggesting that it underwent a liquid-liquid phase transition. Figure 4 D). In summary, these results indicate that particle formation depends on disordered regions, and that the three sites F59, G77, and Y78 are important for the liquid-colloid phase transition of AF9.
[0097] AF9(3A) mutants cannot promote AML in vitro and in vivo.
[0098] We then wanted to know whether AML proliferation and drug resistance required a liquid-gel phase transition of AF9, so we stably overexpressed AF9 and AF9(3A) in OCI-AML3 and Kasumi-1 cells. Figure 7 D). We found that AF9 significantly promoted both short-term and long-term proliferation compared to the control, but AF9(3A) had no effect on proliferation. Figure 5 A-5C). Furthermore, IDA-induced apoptosis was reduced after AF9 overexpression, but AF9(3A) failed to protect AML cells during chemotherapy. Figure 5 D and 5E). These results indicate that AF9(3A) can undergo a liquid-liquid phase transition but loses its ability to promote AML. We then transplanted OCI-AML cells overexpressing AF9 and AF9(3A) into NSG mice and found that the AF9-overexpressing cells produced more granules, indicating that AF9 and AF9(3A) also undergo phase transitions in vivo. Figure 5 F). Meanwhile, mice transplanted with AF9-overexpressing cells had more severe disease than the control group, but there was no significant difference in the AF9(3A) group. Figure 5 G). Flow cytometry results from bone marrow and spleen, as well as spleen weight, also indicated that AF9(3A) had no effect on AML cell proliferation or drug resistance in vivo. Figure 5 Finally, we performed RNA-seq to explore the molecular mechanism by which gel-like AF9 promotes AML while liquid-like AF9 (3A) does not, and found that many signaling pathways are activated, such as cell cycle and cell division. Figure 5 I). These results indicate that the AF9(3A) mutant undergoes a liquid-liquid phase transition due to the inability to activate signaling pathways, but does not promote AML proliferation or drug resistance.
[0099] The AF9(59-78) peptide influences AML progression by interfering with the binding of AF9 to TRiC and reversing the AF9 liquid-gel phase transition to liquid-liquid phase transition.
[0100] Subsequently, we performed mass spectrometry analysis and found that 50 proteins interacted with AF9 but not with AF9(3A). Figure 6 A). Interestingly, four of the 50 proteins are constituents of TRiC: CCT1, CCT3, CCT6A, and CCT7. We then performed a Co-IP immunoprecipitation assay to verify the interaction between AF9 and these proteins, finding that CCT6A interacted most strongly with AF9. Figure 6 B), and AF9(3A) does not bind to CCT6A ( Figure 6 C). TRiC is a complex chaperone protein that mediates the folding of many proteins. The misfolding of AF9(3A) may be the reason why it cannot promote leukemia pathogenesis and drug resistance. An important function of fully folded proteins is to interact with proteins to form functional complexes, so we first investigated whether AF9(3A) could bind to a classic AF9-interacting protein, c-Myc. Immunoprecipitation and immunofluorescence experiments showed that AF9 and c-Myc interact, but AF9(3A) could not. Figure 6 D-6F). These results demonstrate that misfolded liquid AF9(3A) loses its ability to form a properly functioning complex. To interfere with AF9 folding and liquid-gel phase transition to inhibit leukemia pathogenesis and drug resistance, we constructed a plasmid expressing the small peptide AF9(59-78) (its nucleotide sequence is shown in SEQ ID NO. 1), which can mask three important binding sites between AF9 and TRiC (…). Figure 6 G). Immunoprecipitation experiments confirmed that the small peptide successfully prevented the binding of AF9 and CCT6A. Figure 6 H). Furthermore, co-overexpression of AF9 (59-78) peptide and AF9 resulted in less precipitation but greater fluidity (AF9). Figure 6 The I-6K assay demonstrates that the AF9(59-78) peptide mediates the misfolding of AF9, thereby reversing the liquid-gel phase transition to a liquid-liquid phase transition. Then, we performed EdU and CCK-8 experiments, which showed that the AF9(59-78) peptide can inhibit AML cell proliferation. Figure 6 L and 6M). Simultaneously, the AF9(59-78) peptide increased the sensitivity of AML cells to IDA (L and 6M). Figure 6 In summary, the AF9(59-78) peptide affects AF9 folding, reverses the liquid-gel phase transition to liquid-liquid phase transition, thereby inhibiting the proliferation and drug resistance of AML cells, and has great potential for application in AML treatment.
[0101] In summary, we found that AF9 promotes the proliferation and drug resistance of AML. Studies have shown that AF9 can affect many cellular processes, such as cell differentiation, cell fate determination, and nervous system development. However, only one recent study showed that AF9 is highly expressed in human hematopoietic stem cells in the hematopoietic system, thereby preventing differentiation and maintaining self-renewal capacity. Although the importance of MLL-AF9 in AML is well known, the function of AF9 in AML remains unclear. Our study confirms the importance of AF9 in the proliferation and drug resistance of AML, giving us a better understanding of the role of AF9 in AML and providing new evidence for better application of AF9 in the diagnosis and treatment of AML. However, besides the overactivation of MLL target genes in MLL-AF9-induced AML, whether and how its pathogenesis is related to abnormal AF9 function remains to be investigated.
[0102] Meanwhile, AF9 is known to recognize acetylated substrates. Although studies have identified several acetylation reading-related sites, simultaneous mutations at these three sites have not been shown to have an impact. This study found that these sites may be key amino acids for the proper folding of AF9 to form colloidal particles. Moreover, the AF9 (59-78) peptide covering these three important sites can prevent the liquid-colloid phase transition of AF9 and thus inhibit AML. These data suggest that this peptide can cause acetylation reading impairment by inhibiting the proper folding of AF9.
[0103] Phase transitions are crucial in a range of biological processes, including tumorigenesis. Protein-protein interactions can lead to phase transitions through disordered regions, and the physical interactions between biomolecules can result in the formation of phase transition droplets, providing a suitable microenvironment for the aggregation of many factors. Reported particles are mostly liquid and highly fluid. Our study found that correctly folded AF9 forms colloidal particles, but misfolded AF9 (3A) only forms liquid particles. The AF9 (59-78) peptide can reverse the liquid-colloid phase transition of AF9 to a liquid-liquid phase transition, thereby inhibiting AML progression by suppressing the binding of AF9 to TRiC. These studies vividly depict the dynamic relationship between liquid-colloid and liquid-liquid phase transitions, providing new insights into the formation mechanisms of these two phase transitions from the perspective of protein folding.
[0104] Unfolded protein deposits can aberrantly recruit proteins, leading to interactions that enhance function. TRiC is an important chaperone protein that mediates the folding of many cytoplasmic proteins, especially those with complex topologies. As a member of TRiC, CCT2 promotes the autophagic degradation of solid particles. This study found that TRiC-folded AF9 undergoes a liquid-gel phase transition, while misfolded AF9(3A) only forms a liquid-liquid phase transition, suggesting that TRiC-mediated protein folding may be important for phase transitions in many proteins.
[0105] In summary, our results reveal that properly folded AF9 liquid-gel phase transitions can promote AML. In short, three amino acid sites on AF9 that are crucial for its acetylation reading are essential for binding to TRiC and proper folding. Properly folded AF9 undergoes a liquid-gel phase transition, promoting the formation of an effective functional complex, thereby influencing cell proliferation and drug resistance. The AF9 (59-78) peptide covering these three important sites inhibits AML cell proliferation and drug resistance by suppressing AF9-TRiC binding and the formation of the liquid-gel phase transition. Our data link the biophysical properties of AF9 liquid-gel phase transitions to their pathophysiological function in AML progression, providing a potential tool for AML treatment.
[0106] Matters not covered in this invention are common knowledge.
[0107] The above embodiments are only for illustrating the technical concept and features of the present invention, and are intended to enable those skilled in the art to understand the content of the present invention and implement it accordingly. They should not be construed as limiting the scope of protection of the present invention. All equivalent changes or modifications made in accordance with the spirit and essence of the present invention should be covered within the scope of protection of the present invention.
Claims
1. Application of substances that detect the AF9 encoding gene and its expression products in the preparation of products for the diagnosis or prognostic assessment of acute myeloid leukemia.
2. The use according to claim 1, characterized in that, The prognostic assessment includes at least an assessment of overall survival, drug resistance, and disease severity in AML patients.
3. The use according to claim 1, characterized in that, The substance used to detect the AF9 encoding gene and its expression product is used to detect the transcriptional level of AF9 in the sample based on high-throughput sequencing and / or quantitative PCR and / or probe hybridization; or to detect the expression level of AF9 protein in the sample based on immunoassay.
4. The use according to claim 3, characterized in that, The sample was a bone marrow sample from the subject.
5. The use of any one or more of the following to inhibit the AF9 encoding gene and its expression products and / or substances that reduce its activity: a) Prepare products that inhibit AML drug resistance; b) Prepare products for the treatment of AML; The substance that inhibits the AF9 encoding gene and its expression product and / or reduces its activity includes the AF9 (3A) mutant, which is a mutation of the AF protein, and the mutated amino acids of the AF9 (3A) mutant are F59A, G77A and Y78A. The NCBI accession number of the AF9 protein is NP_004520.
2. Alternatively, the substance that inhibits the AF9 encoding gene and its expression product and / or reduces its activity includes the AF9 (59-78) peptide, the nucleotide sequence of which is shown in SEQ ID NO.
1.
6. The use according to claim 5, characterized in that, The product is a drug or experimental reagent, and the experimental reagent is intended for use in basic research.
7. The use according to claim 6, wherein When the product is a drug, the drug also includes at least one inactive pharmaceutical ingredient.
